The stock of Novavax Inc. (NVAX) was up 4.54% to $155.59 in current market trading at last check. NVAX stock closed the previous session at $148.83. Trading volume was 2.04 million shares, which was lower than the average daily volume of 4.73 million shares over the past 50 days. The NVAX shares have increased by 69.84% over the past 12 months, and by 10.60% over the past week.
Top 5 Tech Stocks to Buy in 2024
Don't let the chaos of rising interest rates, potential recession, tighter credit issues, higher oil prices, and incessant geopolitical issues chase you from the markets. Instead, just wait it out. With too much fear in the market, go bargain hunting with tech stocks. We have complied a report with the five of the best ways to profit within this industry.
"Top 5 AI Stocks to Buy in 2024."
Click here to sign up for our free report & newsletter, plus bonus offer "Elon Musk just Tiggered a BOOM in These Stocks"
Sponsored
NVAX stock has lost -18.55% over the past three months, while it has lost -23.72% over the past six months. There are currently 74.12 million outstanding shares of NVAX, which is valued at $11.22 billion currently. Following an emergency use authorization in Indonesia, NVAX stock is rising.
How the NVAX got to that point?
Novavax Novavax is a biotechnology organization that advances further developed wellbeing worldwide through the revelation, improvement and commercialization of inventive vaccines to forestall genuine irresistible illnesses. NVAX’s restrictive recombinant innovation stage joins the force and speed of hereditary designing to effectively deliver exceptionally immunogenic nanoparticles intended to address earnest worldwide wellbeing needs.
NVAX is leading late-stage clinical preliminaries for NVX-CoV2373, its antibody up-and-comer against SARS-CoV-2, the infection that causes COVID-19. NanoFlu, its quadrivalent flu nanoparticle antibody, met all essential goals in its critical Phase 3 clinical preliminary in more established grown-ups. Both immunization competitors consolidate NVAX’s exclusive saponin-based Matrix-M adjuvant to upgrade the safe reaction and invigorate significant degrees of killing antibodies
Novavax and Serum Institute of India Pvt. Ltd. (SII) today reported that the National Agency of Drug and Food Control of the Republic of Indonesia, or Badan Peng was Obat dan Makanan (Badan POM), has allowed emergency use approval (EUA) for NVAX’s recombinant nanoparticle protein-based COVID-19 immunization with Matrix-M adjuvant.
- It will be produced by SII in India and showcased by SII in Indonesia under the brand name COVOVAX.
- The main approval of NVAX’s COVID-19 vaccine epitomizes its obligation to fair worldwide access and will fill a fundamental requirement for Indonesia, which in spite of being the fourth most crowded country on the planet, keeps on attempting to acquire adequate immunization for its populace.
- The approval likewise denotes the primary administrative approval worldwide of a protein-put together COVID-19 immunization based with respect to Phase 3 clinical information showing adequacy and a great security profile.
- This is a milestone second for NVAX and its accomplice SII. It is the first of numerous approvals that NVAX expects in the coming many months for its immunization all around the world.
Other recording endeavors by NVAX:
Novavax (NVAX) and SII have effectively petitioned for approval of NVAX COVID-19 antibody in India and the Philippines, just as for Emergency Use Listing (EUL) with the World Health Organization (WHO). NVAX as of late additionally finished moving entries for approval of the Novavax antibody with administrative organizations in the United Kingdom, European Union, Canada and Australia.
